Severe Pustular Drug Eruptions From Amivantamab: A Case Series

This case series describes severe pustular drug eruptions, including erosive pustular dermatosis (EPD) with scarring, in three women aged 63, 75, and 77 years treated with amivantamab for stage IV non-small cell lung cancer (NSCLC). The study highlights the first reported case of amivantamab-induced scarring alopecia, as previous cases showed hair regrowth. Despite common cutaneous adverse events with amivantamab, such as acneiform rash, these severe eruptions required permanent discontinuation of the drug. Two patients improved when amivantamab was temporarily held but worsened upon rechallenge. Management strategies include topical and systemic treatments, and early intervention is crucial to minimize treatment interruptions. The findings emphasize the need for awareness of potential severe and scarring eruptions and the importance of early dermatology consultation and psychological support.